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Paraoxonase 1 (PON1) is a high density lipoprotein (HDL)-
associated protein with atherosclerosis-protective and systemic
anti-oxidant functions. We recently showed that PON1,
myeloperoxidase, and HDL bind to one another in vivo forming
a functional ternary complex (Huang, Y., Wu, Z., Riwanto, M.,
Gao, S., Levison, B. S., Gu, X., Fu, X., Wagner, M. A., Besler, C.,
Gerstenecker, G., Zhang, R., Li, X. M., Didonato, A. J., Gogonea,
V., Tang, W. H., et al. (2013) J. Clin. Invest. 123, 3815–3828).
However, specific residues onPON1 involved in theHDL-PON1
interaction remain unclear. Unambiguous identification of pro-
tein residues involved in docking interactions to lipid surfaces
poses considerable methodological challenges. Here we de-
scribe a new strategy that uses a novel synthetic photoactivat-
able and click chemistry-taggable phospholipid probe, which,
when incorporated into HDL, was used to identify amino acid
residues on PON1 that directly interact with the lipoprotein
phospholipid surface. Several specific PON1 residues (Leu-9,
Tyr-185, and Tyr-293) were identified through covalent cross-
links with the lipid probes using affinity isolation coupled to
liquid chromatographywithon-line tandemmass spectrometry.
Based upon the crystal structure for PON1, the identified resi-
dues are all localized in relatively close proximity on the surface
of PON1, defining a domain that binds to theHDL lipid surface.
Site-specific mutagenesis of the identified PON1 residues
(Leu-9, Tyr-185, and Tyr-293), coupled with functional studies,
reveals their importance in PON1 binding to HDL and both
PON1 catalytic activity and stability. Specifically, the residues
identified on PON1 provide important structural insights into
the PON1-HDL interaction.More generally, the new photoacti-
vatable and affinity-tagged lipid probe developed herein should
prove to be a valuable tool for identifying contact sites support-
ing protein interactions with lipid interfaces such as found on
cell membranes or lipoproteins.
Ever since the Framingham heart study revealed the inverse
relationship between high density lipoprotein (HDL) choles-
terol levels and the risk of coronary artery disease, the structure
and biological functions of HDL have been under intense scru-
tiny (1–6). HDL and its major structural protein component,
apolipoprotein A-I (apoA-I), play a pivotal role in mediating
reverse cholesterol transport, which describes the process of
cholesterol removal from peripheral tissues for ultimate elimi-
nation from the body by excretion (2, 7–9). Although facilita-
tion of reverse cholesterol transport through cholesterol accep-
tor activity is considered a major function of HDL particles,
ample evidence shows additional functions exist, such as anti-
oxidant, anti-inflammatory, and anti-tumorigenic activities,
and the shuttling of microRNAs or lipid-signaling molecules
(10–16). HDL is a highly heterogeneous array of distinct parti-
cles, with differing associated proteome and peptidome (17–
22). In addition to exchangeable apolipoproteins, early pro-
teomics studies revealed the HDL-associated proteome
includes known participants critical to hemostasis and throm-
bosis, innate and adaptive immune function, growth factors
and various receptors, and hormone-associated proteins (17,
20). In the years that have followed since the original HDL
proteomics studies, subsequent reports have confirmed and
expanded upon these earlier findings, revealing a remarkably
complexHDL-associated proteome that can differ as a function
of disease status or susceptibility (23–25). Thus, alterations in
HDL function appear to be, at least in part, dictated by changes
in the complement of HDL-associated proteins present, with
distinct HDL particle subpopulations composed of unique and
dynamically changing clusters of specific HDL-associated pro-
teins (24–29).
One subpopulation of HDL particles of interest are those
enriched in paraoxonase 1 (PON1). Early genetic and dietary
studies inmousemodels revealed PON1 to be an atheroprotec-
tive protein (30). Localized to theHDL particle, PON1 has been
shown to contribute to HDL-associated anti-oxidative, anti-
inflammatory, and cholesterol efflux functions (10, 12, 24, 31).
PON1 has also been shown to stimulate HDL-dependent nitric
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oxide (NO) production by endothelial nitric-oxide synthase
(10, 32–34). PON1 possesses both esterase and lactonase cata-
lytic activities in vitro but has unclear substrate(s) in vivo (35). A
role for PON1 protection from atherosclerosis in vivo has been
supported by studies showing PON1 knock-out mice have
accelerated atherosclerosis (36), and human PON1 transgenic
mice demonstrate both protection from atherosclerosis and
reduced indices of systemic oxidative stress (31, 37). In human
studies, a striking correlation between multiple systemic mea-
sures of oxidant stress and serum PON1 activity measures has
also been established (12, 31). Moreover, reduced systemic
PON1 activity has been shown to predict increased prospective
risks for major adverse cardiac events in multiple distinct clin-
ical cohorts (12, 38–41). Thus, there is considerable in vitro
and in vivo evidence to support PON1as an importantmediator
of many anti-inflammatory, anti-oxidant, and atheroprotective
activities of HDL.
Knowledge at the structural level of how HDL-associated
proteins interact with HDL particles is in its infancy. In prior
studies, we showed that HDL forms a functional ternary com-
plex with PON1 and myeloperoxidase (31), an oxidant-gener-
ating enzyme linked to development of atherosclerosis (42–
48). Eachmember of the ternary complex was shown to impact
the function of the other in vivo (31). Residues involved in the
protein-protein interaction between PON1 and apoA-I of
HDL, or between myeloperoxidase and apoA-I of HDL, have
thus far been delineated using hydrogen deuterium exchange
mass spectrometry-basedmethodology as a discovery platform,
coupled with site-specific mutagenesis and functional studies
to determine the significance of the residues involved (31, 49).
Despite themany recent advancesmade, a full understanding of
how PON1 interacts with HDL remains unclear. For example,
PON1 binding to HDL lipid and membrane surfaces is known
to be essential for its stability and catalytic activity (31); how-
ever, the interaction sites between PON1 and the lipid interface
of HDL remain unknown. Indeed, tools for defining contact
residues betweenproteins andphospholipid surfaces such as on
a membrane bilayer, or a lipoprotein particle, are not readily
available.
Herein, we describe development, characterization, and
application of a novel tool to interrogate contact residues that
support tight binding interactions with phospholipid surfaces,
a synthetic photoactivatable and “clickable” phosphatidylcho-
line analogue (pac-PC).3 Using PON1-HDL interactions as a
test case, we illustrate the facile use of this new technology,
defining several key residues on PON1 essential for PON1
docking to HDL, PON1 catalytic activity, and stability. The use
of pac-PC incorporated into recombinant HDL particles or
membrane bilayers may thus serve as a universal strategy to
facilitate identification of residues critical for protein docking
with the lipid surface of lipoproteins or cell membranes.
Experimental Procedures
General Methods—All solvents used for synthesis were dis-
tilled under a nitrogen atmosphere prior to use, and all materi-
als were obtained from Sigma unless specified otherwise. Chro-
matography was performed with ACS-grade solvents. Progress
of synthetic reactions was monitored by thin layer chromatog-
raphy, and Rf values are quoted for silica gel-coated plates of
0.25-mm layer thickness. The plates were visualized with
iodine. Flash column chromatography (50) was performed on
230–400-mesh silica gel supplied by EMD Millipore. Protein
content was measured using the Markwell-modified Lowry
method (51) with bovine serum albumin as a standard. PON1
activity measurements (paraoxonase and arylesterase activi-
ties) were performed as described previously (39). Proton mag-
netic resonance (1H NMR) spectra were recorded on a Varian
Inova AS400 spectrometer operating at 600 MHz. Proton
chemical shifts are reported as parts per million (ppm) on the 
scale relative to CDCl3 ( 7.24). 1H NMR spectral data are tab-
ulated in terms of multiplicity of proton absorption (s, singlet;
d, doublet; t, triplet;m,multiplet; br, broad), coupling constants
(Hz), andnumber of protons. TheUV light source (365 nm)was
supplied by a Spectroline Model ENF-280C lamp suspended
just over the top of the sample tubes.
Chemical Syntheses of 1,2-Dimyristoyl-sn-glycero-3-phospho-
2-(3-methyl-3H-diazirin-3-yl)ethanol—1,2-Dimyristoyl-sn-gly-
cero-3-phosphate (DMPA, 200 mg, 0.33 mmol, Corden-
Pharma, Boulder, CO), 2-(3-methyl-3H-diazirin-3-yl)ethanol
(70 l, 0.7 mmol) (52, 53), and 2,4,6-triisopropylbenzenesulfo-
nyl chloride (300 mg, 0.96 mmol) were dissolved in 10 ml of
anhydrous pyridine, and the reaction mixture was stirred over-
night at room temperature. The reactionwas quenched by add-
ing 0.5 ml of water. Pyridine was removed by rotary evapora-
tion. The residue was suspended in 70 ml of cold ether at 4 °C
overnight. After filtration, the ether was removed by rotary
evaporation. The crude product was purified by silica gel chro-
matography elutingwith 10%methanol in chloroform to obtain
the pure product (139.4 mg, yield 63%, Rf 0.37 (CHCl3/
CH3OH/H2O 15:5:0.5)). 1H NMR (600 MHz, CDCl3)  5.28
(br, 1H), 4.42 (br, 1H), 4.18 (br, 1H), 3.98 (br, 2H), 3.77 (br, 2H),
2.40–2.20 (4H), 1.70–1.50 (6H), 1.30–1.10 (40H), 1.03 (s, 3H),
0.85 (t, 6H).Negative ESI-MS/MSanalysis yielded the following
diagnostic parent and fragment ions:m/z 673.8 [MH];m/z
645.6, 435.5, 227.6.
Chemical Syntheses of 1-Myristoyl-sn-glycero-3-phospho-2-
(3-methyl-3H-diazirin-3-yl)ethanol—1,2-Dimyristoyl-sn-gly-
cero-3-phosphatidyl-2-(3-methyl-3H-diazirin-3-yl)ethanol (100
mg, 0.15 mmol) in a 50-ml centrifuge tube as dry film was sus-
pended in 20 ml of PBS buffer (10 mM, pH 8.0, and containing
CaCl2 5 mM) and was vortexed for 5 min. 500 l of phospho-
lipase A2 (100 units, Sigma P6534-10MG) was added. The
resulting mixture was gently vortexed for another 2 min and
incubated at 37 °C in a shaker overnight. Lipids were extracted
by the Bligh and Dyer method (54), and the aqueous phase was
extracted with chloroform (10 ml 2 times). Organic solvents
were combined and evaporated. The crude product was puri-
fied on a silica gel column eluting with 15% methanol in chlo-
roform to obtain the pure product (45 mg, yield 65%, Rf 0.2,
3 The abbreviations used are: pac-PC, photoactivatable and clickable-phos-
phatidylcholine; rHDL, reconstitutednascentHDL;Ni-NTA, nickel-nitrilotri-
acetic acid; DMPA, 1,2-dimyristoyl-sn-glycero-3-phosphate; SPR, surface
plasmon resonance.
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25% methanol in chloroform). Negative ESI-MS/MS analysis
yielded the following parent and diagnostic fragment ions:m/z
463.7 [M H];m/z 435.6, 365.5, 227.7.
Chemical Syntheses of 1-Myristoyl-2-(10-undecynoyl)-sn-
glycero-3-phospho-2-(3-methyl-3H-diazirin-3-yl)ethanol (pac-PC)—
1-Myristoyl-sn-glycero-3-phosphatidyl-2-(3-methyl-3H-diazi-
rin-3-yl)ethanol (20 mg, 0.043 mmol), 10-undecynoic acid (40
mg, 0.22 mmol), N,N-dicyclohexylcarbodiimide (26 mg, 0.126
mmol), and 4-dimethylaminopyridine (5mg, 0.043mmol) were
dissolved in 2 ml of anhydrous chloroform and stirred at room
temperature for 48 h. Solvents were removed by rotary evapo-
ration. The crude product was purified on a silica gel column
eluted with 10% methanol in chloroform to deliver the final
product (20.4 mg, yield 75%, Rf  0.36 with 20% methanol in
chloroform). 1H NMR (600 MHz, CDCl3)  5.28 (br, 1H), 4.35
(br, 2H), 4.14 (br, 2H), 4.02 (br, 1H), 3.82 (br, 1H), 2.40–2.20
(4H), 2.20–2.10 (2H), 1.92 (m, 1H), 1.70–1.55 (6H), 1.50 (m,
2H), 1.30–1.10 (28H), 1.04 (s, 3H), 0.86 (t, 3H). Negative ESI-
MS/MS analysis yielded the following diagnostic parent and
fragment ions: m/z 627.7 [M  H]; m/z 599.5, 435.5, 228.3,
182.1.
Preparation of Reconstituted Nascent HDL Containing
pac-PC—All human biological materials were obtained from
participants that gave written informed consent for protocols
approved by the Cleveland Clinic Institutional Review Board.
HumanHDLwas isolated from plasma of healthy volunteers by
sequential buoyant density ultracentrifugation using KBr to
adjust density to the range of 1.07–1.21 g/ml, as described pre-
viously (55–57). Lipid-free human apoA-I was prepared by
delipidation of isolated human HDL using methanol/ether/
chloroform followed by ion exchange chromatography. The
purity of isolated human apoA-I was verified by SDS-PAGE.
Reconstituted nascent HDL (rHDL) was prepared using the
sodium cholate dialysis method ofMatz and Jonas (58) as mod-
ified by Barter and co-workers (59). An initial molar ratio of
98:2:10:1 of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line/pac-PC/cholesterol/isolated human apoA-I was used for
reconstituted HDL preparation.
Photoactivatable Cross-linking between pac-PC and Human
apoA-I or PON1—Control studies showed that pac-PC is stable
(at least on the time scale of many minutes to hour) under
normal ambient light conditions. All studies described were
performed under ambient light conditions. Nonetheless, expo-
sure of pac-PC to light was minimized at all times (except for
UV exposure), by keeping the photo-lipid in screw cap glass
reaction vials wrapped in foil.
(i) The cross-linking between pac-PC and human apoA-I/
rHDL with pac-PC (human apoA-I concentration of 70 M) in
0.5 ml of 50 mM PBS buffer at pH 7.0 was transferred into small
glass vials on ice and then directly exposed to 365 nm UV light
for 1 min. Proteins were then precipitated by adding 9 ml of
methanol/chloroform/ether, 1:1:2.5 (v/v/v).
(ii) The cross-linking between pac-PC and PON1/rHDLwith
pac-PC (human apoA-I concentration of 70 M) in 0.5 ml of 50
mM PBS buffer at pH 7.0 was incubated with recombinant His-
tagged PON1 (rPON1, 30 M, in 0.5 ml of 50 mM Tris buffer
with 1 mMCaCl2, pH 7.0) that was expressed and purified from
Escherichia coli, as described previously (60). The mixture was
incubated at 37 °C for 1 h. This mixture was then transferred
into small glass vials on ice and directly exposed to a 365-nm
UV light for 1min. Proteinswere thenprecipitated by adding 18
ml of methanol/chloroform/ether, 1:1:2.5 (v/v/v). The precipi-
tated proteins (mixture of apoA-I and PON1) were dissolved in
1 ml of PBS buffer (50 mM, pH 7.0) with 1% SDS and diluted by
addition of 4 ml of PBS buffer (to reduce SDS concentration to
0.2%). Nickel-nitrilotriacetic acid resin (Ni-NTA, 500 l, pre-
washed and equilibrated in PBS buffer, 50 mM, pH 7.0) was
added to enrich His-tagged PON1 and to remove human
apoA-I. rPON1 was eluted with PBS buffer (50 mM, pH 7.0)
containing 0.2% SDS and 200 mM imidazole. rPON1 was again
precipitated by using methanol/chloroform/ether, 1:1:2.5
(v/v/v).
Adding Biotin Tag to pac-PC Cross-linked Proteins through
Click Chemistry—Precipitated protein (apoA-I or rPON1) that
had been cross-linked with the pac-PC was dissolved in 1 ml of
PBS buffer (50 mM, pH 7.0, and with 1% SDS). Biotin-azide (61)
(4 l, 30 mM in dimethylformamide) was added, and the mix-
ture was vortexed for 1min. Then, freshlymade tris(2-carboxy-
ethyl)phosphine (20l, 50mM inwater) was added, followed by
the addition of tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]
amine (20l, 5mM inDMSO/t-butanol 1:4), and themixture
was vortexed for another 1min. The reaction was initiated with
CuSO4 (50 l, 20 mM stock solution in water) and the mixture
was vortexed for 1 min. The reaction mixture was left at room
temperature for 1 h (and vortexed after 30min). Reaction prod-
uct was transferred into Slide-a-Lyzer dialysis cassettes
(ThermoScientific) and dialyzed against 4 liters of PBS buffer at
4 °C (buffer changed three times in 24 h).
Affinity Purification of pac-PC-modified Peptides—The affin-
ity purification of pac-PC cross-linked proteins and subsequent
on-bead trypsin/chymotrypsin digestion steps were performed
using the general tandem orthogonal proteolysis strategy
described by Weerapana et al. (62). Briefly, photoactivatable
lipid probe (pac-PC) cross-linked and biotin-tagged proteins
(apoA-I or rPON1)were incubatedwith neutravidin beads (200
l, 1:1 slurry, pre-washed and equilibrated in PBS buffer) for 3 h
at room temperature. Supernatant was removed by centrifuga-
tion at 1400 g for 3 min. Neutravidin beads were washed by 5
ml of PBS (with 0.2% SDS) three times and followed by 5 ml of
water. Beads were transferred into a low retention Eppendorf
tube and incubated with a premixed solution (200 l of 1 M
urea/PBS, 2 l of 1 M calcium chloride in water, and 4 l of 0.5
g/l trypsin or chymotrypsin) at 37 °C overnight with rota-
tions. Neutravidin beads were washed with PBS buffer (3 500
l) and water (3 500l). To release the biotinylated peptides
from neutravidin beads, the beads were treated with 50:50 (v/v)
water/acetonitrile containing 0.1% trifluoroacetic acid (200 l,
65 °C, 5 min) as described previously (63). Beads were removed
via filtration through a spin column and washed with 50:50
(v/v) water/acetonitrile (2 100 l) for a total elution volume
of 400 l. The solvent was evaporated under N2 flow to a final
volume of 25 l and was diluted by another 25 l of 0.1%
formic acid/water. For the base treatment, sodiumhydroxide (1
M in water, 5 l) was added, and the resulting mixture was
incubated at room temperature for 3 h. Then acetic acid (2 M in
water, 3 l) was added to neutralize the sample. The samples
Photoaffinity Probe to Define Protein, Phospholipid Contacts
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were analyzed by liquid chromatography with on-line electro-
spray ionization tandem mass spectrometry (LC/MS/MS).
Mass Spectrometry Analysis—All mass spectrometry analy-
ses were performed under the Xcalibur data system using
ProxeonEasy-nLCcoupled to a LTQOrbitrapVelosmass spec-
trometer (Thermo Scientific) with a nano-LC electrospray ion-
ization source. Sampleswere first pressure-loaded onto an Inte-
graFrit sample trap (inner diameter 100m, length 2.5 cm,New
Objective) and separated by a PicoFrit column (stock number
PF360-75-15-N-5, New Objective) packed in our laboratory
(packing material: C18, 300 Å, 5 m from Cobert Associates).
Mobile phase was as follows: buffer A/water with 0.1% formic
acid; buffer B/acetonitrile with 0.1% formic acid. The HPLC
gradient started with 5% B and increased to 40% B over 60 min,
then increased to 80% B over 5 min, and held at 80% B for
another 10 min. For repeat injections on autosampler, the col-
umn was re-equilibrated for the next sample by decreasing to
5%Bover 2min andheld at this solvent composition for 20min.
Flow rate was 0.2 l/min. The applied spray voltage of the
nano-LC electrospray ionization source was 2.0 kV. For MS2
data collection, one full scan by Orbitrap was followed by 10
data-dependent scans of the most intense ions by ion trap.
Dynamic exclusion was also applied so that any ions that had
been repeatedly scanned three times in 60 s would be excluded
for scan for 3 min.
Mass spectra were subject to SEQUEST (64) (Thermo Scien-
tific) and searched against a PON1.fasta database. A staticmod-
ification 926.532, corresponding to the lipid probe, was
applied to each amino acid residue. SEQUEST output files were
filtered by XCorr (cross-correlation value, minimal XCorr 
1.8(1), 2.5(2), 3.5(3) as described in the DTASelect (65)).
For base-treated samples, a static modification of 226.061
corresponding to a glycerol phosphate group was used. Other
possible modifications were also applied during the SEQUEST
search, including oxidation onmethionine (16), deamination
of glutamine and asparagine (1), and dehydration of serine
and threonine (18). All targeted peptides spectra were exam-
ined by manual inspection.
Site-specific Mutations of Recombinant Paraoxonase 1
(rPON1)—Site-specific mutants of rPON1 used included the
G3C9 PON1 clone (60) on the wild type (WT) backbone
sequence. The pan-E PON1 mutant (L9E, Y185E, and Y29E),
pan-K PON1 mutant (L9K, Y185K, and Y293K), PON1
(Y293K), and PON1 (Y294K) with a His8 tag directly at their C
terminus were prepared from codon-optimized WT rPON1
directly synthesized by GenScript (Piscataway, NJ) and cloned
at NcoI-HindIII restriction sites into the pBAD vector (Invitro-
gen). Competent TOP10 (Invitrogen) E. coli cells were trans-
fected with the plasmids for the expression of the recombinant
proteins. Wild type and mutant rPON1s were purified by Ni-
NTA affinity chromatography to homogeneity, with purity of
proteins confirmed by SDS-PAGE.
Spectral Studies of rPON1 Mutants—Far-UV circular dichr-
oism spectra were recorded on a Pistar180 spectropolarimeter
(Applied Photophysics, Surrey, UK). Standardization was per-
formed with an aqueous solution of 0.06% ammonium d-()-
10-camphor sulfonate at a wavelengths of 260 to 200 nm and
with a path length of 10 mm. rPON1 forms (WT, pan-E, and
pan-K mutants) were prepared as 0.1 mg/ml samples in 10 mM
phosphate buffer, pH 7.0, supplemented with 0.2 mM CaCl2,
and analyzed at ambient temperature in continuous scanmode
with a 1-nm bandwidth (100,000 counts/step).
Surface Plasmon Resonance (SPR)—Full time course kinetic
determinations of kon, koff, and apparent equilibrium dissocia-
tion constantsKd for rHDL interactionwith rPON1 formswere
determined using SPR using a BIAcore 3000 SPR biosensor
(BIAcore, AB). Briefly, rHDL was directly immobilized on a
CM5 sensor chip. To determine the Kd value between distinct
rPON1 and rHDL, rPON1 ranging from 500 to 2000 nM were
prepared in PON1 activity buffer (50 mM Tris, 50 mM NaCl, 1
mM CaCl2, pH 8.0) and flowed over the surface of the sensor
chip at a rate of 20 l/min. At the end of each cycle, surfaces of
the sensor chips were regenerated by injection of 15 mMHCl at
the same flow rate. ApparentKd values were obtained by fitting
background-subtracted SPR binding data to the 1:1 binding
with drifting baseline model within the BIAevaluation software
version 4.0.
Stability Studies of rPON1 Mutants—rPON1 was preincu-
bated with rHDLs (2 eq) or 0.1% tergitol (NP-10, Sigma) in
PON1 activity buffer (50 mM Tris, 50 mM NaCl, and 1 mM
CaCl2, pH 8.0) at 37 °C for 30min. Inactivation was initiated by
adding an equal volume of inactivation buffer (10 mM EDTA
and 20mM-mercaptoethanol in 50mMTris, pH8.0) and incu-
bating the samples at 37 °C. Aliquots were taken at various time
points, and the arylesterase activity was examined as described
previously (39).
Results
Photoactivatable Lipid Probe Design and Chemical Syn-
thesis—Plasma HDL particles represent an ensemble of lipi-
dated apoA-I core lipoprotein (75% protein mass of HDL) with
numerous distinct interacting HDL-associated proteins.
Remarkably, despite the interest in HDL biology and the role in
cardiovascular disease, an understanding of the structural
regions on virtually all HDL-associated proteins critical for
docking to the lipoprotein lipid surface is poorly defined. This is
because few specific and effective tools exist for direct detection
of protein contact points with lipid surfaces, whether it be a
lipoprotein, a cell membrane, or a microparticle. To address
this unmet need, we designed a photoactivatable and clickable
phospholipid probe, pac-PC (Fig. 1A). Phosphatidylcholine is
the most abundant class of phospholipid in most lipoproteins
and membranes. Our photoaffinity lipid (pac-PC) is an ana-
logue of phosphatidylcholine, which harbors a diazirine ring
that replaced the trimethylamine moiety of the choline polar
headgroup. Upon exposure to ultraviolet (UV, 365 nm) radia-
tion, the diazirine ring readily expels N2 generating a reactive
diradical carbene species. Carbenes rapidly insert into proxi-
mate protein backbones or side chains in nanoseconds, and if
not are then scavenged by water at near the diffusion-limited
rate. Thus, our probe design ensures that detection of a cova-
lent adduct between the phospholipid probe and a protein indi-
cates the existence of a tight enough binding interaction to
exclude water (66). In addition, to facilitate subsequent affinity
isolation of adducts, we also introduced a terminal alkyne group
on an sn-2 position aliphatic chain, providing a useful handle
Photoaffinity Probe to Define Protein, Phospholipid Contacts
JANUARY 22, 2016•VOLUME 291•NUMBER 4 JOURNAL OF BIOLOGICAL CHEMISTRY 1893
 at Cleveland State U
niversity on M
arch 22, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
for the later addition of a biotin tag through highly efficient and
selective click chemistry (Fig. 1A) (67, 68).
The synthetic route to the new lipid probe, pac-PC, is shown
in Fig. 1B. The chemical synthesis is described in detail under
“Experimental Procedures” and began from a commercially
available lipid (DMPA). Briefly, after being coupled with 2-(3-
methyl-3H-diazirin-3-yl)ethanol (69), the sn-2 side chain was
removed through phospholipase A2-catalyzed hydrolysis (70).
Further reaction of the lysolipid with 10-undecynoic acid in
the presence of coupling reagents dicyclohexylcarbodiimide
and 4-dimethylaminopyridine delivered the final product,
pac-PC (71). The synthesized lipid probe was purified by
HPLC and extensively characterized by nuclear magnetic
resonance (NMR) and mass spectrometry to confirm its
purity and validate its structure, as outlined under “Experi-
mental Procedures.”
Photoactivatable Lipid (pac-PC) Cross-linked with ApoA-I in
HDL—Photoactivatable lipids have been used to isolate and
identify proteins that interact with lipids (72). However, subse-
quent mass spectrometry analyses to define the exact contact
residues of target proteins remain a daunting challenge, as the
methods to selectively identify precisely the amino acid resi-
dues has not yet been developed. Because apoA-I interacts with
phospholipids in nascent HDL particles, we initially examined
the interaction of pac-PC with apoA-I in HDL to develop the
necessary analytical and mass spectrometry methods. The
experimental schemewe used to study lipid-protein interaction
in nascent HDL is outlined in Fig. 2. rHDL was prepared as
outlined under “Experimental Procedures” using a modified
sodium cholate dialysis method containing a low mol % of the
photoactivatable lipid probe, pac-PC, to minimize potential
structural perturbations to the particle. Control studies (equi-
librium native PAGE and dual beam light scattering) showed
that the rHDL particles thus generated had similar size com-
paredwith rHDL lacking the probe (data not shown). Following
exposure toUV irradiation, the pac-PC adductwas biotinylated
using click chemistry as outlined under “Experimental Proce-
dures.” Tagged apoA-I was then subject to neutravidin affinity
column enrichment followed by on-bead trypsin digestion, as
described under “Experimental Procedures.” Following a wash
step, pac-PC-modified apoA-I peptides were eluted from the
beads and then analyzed by LC/MS/MS (Fig. 2).
Despite initial efforts to deconvolute the raw spectra with
SEQUEST searches, nomodified peptides were identified (even
when the XCorr values were lowered to 1.0(1), 2.0(2),
3.0(3)). However, manual inspection of the raw peptide spec-
FIGURE 1. Design and chemical synthesis of the lipid probe pac-PC. A,
chemical structure of pac-PC. pac-PC is an analogue of phosphatidylcholine,
with two extra function groups as follows: one diazirine group (in dashed
circle) on sn-3 headgroup and one alkyne group (in dashed square) on sn-2
fatty acid side chain terminal. The carbene di-radical (in dashed circle) is gen-
eratedafterUV irradiation. The terminal alkyne reactswithbiotin azide togive
a triazole (in dashed square). B, chemical synthesis of pac-PC began from a
commercially available lipid (DMPA). Briefly, after being coupled with 2-(3-
methyl-3H-diazirin-3-yl)ethanol, the sn-2 side chain was removed through
phospholipase A2-catalyzed hydrolysis. Further reaction of the lyso-lipidwith
10-undecynoic acid in the presence of coupling reagents dicyclohexylcarbo-
diimide (DCC) and 4-dimethylaminopyridine (DMAP) delivered the final prod-
uct, pac-PC. Details are under “Experimental Procedures.”
FIGURE 2. Experimental scheme using pac-PC to investigate pac-PC-
apoA-I interaction. rHDL was prepared as described under “Experimental
Procedures” and contained 2 mol % of pac-PC. After UV irradiation, the pac-
PC/apoA-I cross-linkingproductswerebiotinylatedusing click chemistry. Bio-
tin-tagged pac-PC/apoA-I adducts were enriched by neutravidin collection
and trypsinized, and unbound peptides were washed away. Following the
wash step, pac-PC-modified apoA-I peptides were eluted from the beads. In
later experiments, base hydrolysis of pac-PC-modified peptides was incorpo-
rated at this step to remove the bulk of the lipid side chains allowing accurate
software interrogation ofmodified peptide adducts by analysis using LC/MS/
MS. Details are under “Experimental Procedures.”
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tra identified abundant spectrawith specific daughter fragmen-
tations (ions produced during MS/MS ionization), such asm/z
284 and m/z 775 (one example is given in Fig. 3A) (note: our
method involves two wash steps, which removed non-labeled
apoA-I protein and non-labeled apoA-I peptides, and it made
the manual inspection of the raw spectra possible). Identical
daughter fragmentations (m/z 284 andm/z 775) from different
peptide spectra suggested that the daughter ions atm/z 284 and
m/z 775 were derived from the same source, the lipidmodifica-
tion. To test our hypothesis, we performed a control experi-
ment as illustrated in Fig. 4. The synthetic lipid analogue, pac-
PC, was either incorporated into HDL (i.e. in the presence of
protein), as outlined above, or incubated alone in buffer (PBS)
and then exposed to UV irradiation. Samples were then incu-
batedwith biotin azide to enable click chemistry-based biotiny-
lation, followed by on-bead trypsin digestion and LC/MS/MS
analysis (Fig. 4). The pac-PC sample exposed to UV irradiation
alone in buffer (without the presence of apoA1/HDL), during
MS ionization, gave rise tom/z 284 andm/z 775 as major frag-
ments, confirming that these daughter ions arise from the
pac-PC moiety itself. Thus, the reasons for difficulty using the
automated peptide sequencing was because the lipid-modified
peptides gave dominant fragments from cleavage of the lipid
instead of from the peptide backbone, complicating spectra
interpretation and resulting in failed software searches.
To circumvent this problem, we added a simple base hydro-
lysis step to the end of the overall scheme depicted in Fig. 4, the
rationale forwhich is illustrated in the scheme shown in Fig. 5A.
The ester bonds in lipids are more base-sensitive than amide
bonds in peptides; thus, base-catalyzed hydrolysis effectively
removed the bulk of the lipid fatty acid side chains leaving a
characteristic small modification group (glycerol phosphate,
226.061 atomic mass units). For base-treated samples, we
therefore applied a static modification of 226.061 atomic
mass units to each amino acid for peptide analyses, correspond-
ing to a glycerol phosphate group, as described under “Experi-
mental Procedures.” We found that applying this static
226.061 atomic mass unit modification gave structurally
informative and recognizable peptide backbone fragmenta-
tions (Fig. 5). Thus, base-treated peptides were easily identified
and recognized with exact modification sites by SEQUEST. As
expected, examination of peptide spectra from pac-PC-con-
taining rHDL showed that numerous residues throughout the
length of apoA1 may be covalently tagged by pac-PC (one
example is given in Fig. 5).
Use of rHDL Incorporating pac-PC to Identify PON1 Residues
Involved in Binding to the HDL Lipid Surface—Having refined
the above sample processing and mass spectrometry analyses
using this new tool, we next applied it to the study of HDL-
PON1 interaction, a test case to validate the utility of pac-PC in
defining HDL-associated protein contact sites. A step by step
scheme depicting the overall steps is shown in Fig. 6. Reconsti-
tuted nascent HDL incorporating low mol % (2%) pac-PC was
prepared and then incubated with His-tagged rPON1 at 37 °C
for 1 h. Cross-linking was performed as described under
“Experimental Procedures” with brief (1 min) exposure to UV
light (365 nm) at 0 °C. Proteins were precipitated, and then
resolubilized rPON1 was enriched using Ni-NTA resin (to
remove human apoA-I). Immobilized PON1-containing phos-
pholipid adducts were biotinylated via click chemistry, and
then lipid-tagged rPON1 was subjected to neutravidin enrich-
ment and on-bead trypsin/chymotrypsin digestion (Fig. 6). Fol-
lowing a wash step to remove non-labeled peptides, the lipid-
modified rPON1 peptides were eluted from the beads. After
base treatment, facile identification of themodification sites on
rPON1was achieved by LC/MS/MS and searching for glycerol-
phosphate modified peptides, which were detected by a static
modification (226.061) applied to each amino acid residue.
Three rPON1 peptides (Table 1) were reproducibly identi-
fied that carried the specific modification (226.061) corre-
sponding to the glycerol phosphate adduct (Ala2-Lys21, Ile291-
Lys297, and Ala180-Tyr-190). The residue within each peptide
(Leu-9, Tyr-185 and Tyr-293) carrying the glycerol-phosphate
moiety derived frompac-PC is also shown, alongwith the excel-
lent (within 10 ppm) agreement between the exact mass exper-
imentally measured for each peptide and its theoretical mass
based on elemental composition (Table 1). For illustrative pur-
FIGURE 3. pac-PC-labeled peptides have unique fragmentation patterns
derived from pac-PC. A, one representative tandemmass spectrum of pac-
PC-modified apoA-I peptide (Thr161-Arg171) having the diagnostic fragments
m/z 284 andm/z 775. B, tandemmass spectrum of pac-PC after photoactiva-
tion (in PBS buffer) and click chemistry reaction, which has dominant frag-
mentsm/z 284 andm/z 775.
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poses, the mass spectra of the native peptide Ile291-Lys297 and
the peptide Ile291-Lys297 carrying the modification at residue
Tyr-293 are presented in Fig. 7,A and B, respectively. Note that
a static mass shift of 226 is observed on related b and y ions
labeled with * in Fig. 7B. Also shown (Fig. 8) is the crystal struc-
ture for PON1 (73) with superimposed locations of Leu-9, Tyr-
185, andTyr-293, which collectively identify the interfacial sur-
face that binds to theHDL particle. Of interest, PON1Tyr-71, a
residue we previously showed was in close spatial proximity to
cholesterol within PON1 bound to an HDL particle using a
photoaffinity-labeled cholesterol analogue (31), is similarly
localized close to the identified HDL-binding interface (Fig. 8).
Also of interest and discussed below, PON1 Tyr-294, despite
being within5 Åwith Tyr-293 (-carbon to -carbon; Fig. 8),
failed to show pac-PC probe adduct formation in PON1-bound
HDL, illustrating the remarkable specificity of residue interac-
tion and covalent modification by the phospholipid photoacti-
vatable group in the PON1-HDL complex.
As noted above, the rPON1 variant used in this study, G3C9,
has two adjacent tyrosine residues (Tyr-293 and Tyr-294) in
peptide Ile291-Lys297, but sequence analyses of affinity-isolated
peptides recovered from PON1-HDL complexes following
photoactivation of the pac-PC probe repeatedly showed only
PON1 Tyr-293 was covalently adducted to the probe. To con-
firm that the lipid cross-link was at Tyr-293 instead of Tyr-294,
we performed the more sensitive analysis of selected ion mon-
itoring (m/z 586.3, corresponding to the lipid cross-linked pep-
tide Ile291-Lys297) and collected its daughter fragments. We
were able to successfully isolate a peptide that has the samem/z
value but slightly different retention time, shown as the small
shoulder peak (peak 1) on the chromatogram (Fig. 9A). This less
abundant peptide, Ile291-Lys297, was observed to carry the lipid
modification at Tyr-294 instead of Tyr-293, based on its
MS/MS fragments (Fig. 9B; adduct at Tyr-294 is estimated to
occur at a 10–20-fold reduced level compared with adduct at
Tyr-293).
PON1 Residues Leu-9, Tyr-185, and Tyr-293 Are Function-
ally Important for HDL Binding and Preservation of PON1
Activity—To examine the functional significance of PON1 res-
idues discovered as HDL lipid-binding sites (Leu-9, Tyr-185,
and Tyr-293), we generated site-specific rPON1 mutants. All
mutants were compared with the recombinant PON1 variant
G3C9 (wild type-like activity, rPON1 WT). Residues (Leu-9,
Tyr-185, and Tyr-293) were mutated to either glutamic acid
(rPON1 pan-E) or lysine (rPON1 pan-K). The purified rPON1
mutants (pan-E or pan-K mutants) were observed to be homo-
geneous and have similar molecular weight, as shown by SDS-
PAGE (Fig. 10A). Moreover, secondary structure analyses, as
shown by circular dichroism (CD) spectra, revealed minimal
differences when compared with WT rPON1 (Fig. 10B). We
examined the catalytic activities of WT rPON1 and these
rPON1 mutants by using paraoxon (paraoxonase activity) or
phenyl acetate (arylesterase activity) as substrates. Purified
rPON1 pan-Kmutant demonstrated a specific activity of50%
paraoxonase activity and80% arylesterase activity compared
with rPON1WT, whereas rPON1 pan-Emutant demonstrated
almost complete loss of activity with either substrate (Fig. 11,A
and B).
We interrogated the functional significance of PON1 resi-
dues Leu-9, Tyr-185 and Tyr-293 in HDL docking interactions
FIGURE4.MajorMS/MS fragmentsof pac-PC-modifiedpeptides come from lipidportion. The control experimentwasperformedbyusingpac-PC vesicles
in PBS buffer. For comparison, the steps for use and analysis of pac-PC-coupled peptides following interaction with protein (as in rHDL) are also shown. After
UV irradiation, pac-PC isbiotinylated throughclick chemistry andaffinity-isolated, subjected to trypsinolysis, andanalyzedbyLC/MS/MS. In theexampleofonly
pac-PC exposed to UV irradiation in buffer alone, the final extracted lipid gave m/z 284 and m/z 775 as major MS/MS fragments, typical patterns from
pac-PC-modified peptides. Thus, fragment ionsm/z 284 andm/z 775 originate from the lipid portion of lipid-adducted peptides.
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by directly quantifying the collective role of the PON1 residues
in binding to the HDL particle surface. For these studies, the
binding of WT rPON1 (G3C9) and both mutant rPON1 forms
(pan-E and pan-K) with rHDL were examined using surface
plasmon resonance spectroscopy. Reconstituted HDL particles
were directly coated on the sensor chips, and then diluted
rPON1 solutions of different concentrations were individually
flowed over the immobilized rHDL. Measured kon, koff, and Kd
values for each PON1 form interactionwith rHDL are shown in
Table 2, and for illustrative purposes, typical binding sensor-
grams for binding of rPON1WT or rPON1 pan-K to rHDL are
presented in Fig. 12, A and B, respectively. Of note, the rPON1
pan-Kmutant showed 1000-fold less binding capacity to rHDL
compared with rPON1WT (Kd, 1.4 106 versus 7.1 1010,
respectively, see Table 2). The rPON1 pan-E mutant showed
even lower HDL binding capacity compared with the rPON1
pan-K mutant (Kd, 5.9 105 versus 1.4 106, respectively,
seeTable 2). These results show that PON1Leu-9, Tyr-185, and
Tyr-293 participate in PON1-HDL interactions, and the nature
of the site-specific mutations impact the affinity of the PON1
form to bind to HDL.
PON1 binding to HDL is known to stabilize PON1 catalytic
activity at 37 °C, with both protein (apoA-I) and lipid phase of
HDL contributing to the overall docking and stabilization of
PON1 on the HDL particle (31, 74, 75). We therefore next ana-
lyzed the importance of PON1 Leu-9, Tyr-185, and Tyr-293 in
PON1 stabilization with HDL particles. To speed inactivation,
rPON1 (WT versus pan-K form) was incubated with a calcium
chelator (EDTA) and a reducing agent, -mercaptoethanol, in
the presence or absence of rHDL or detergent (0.1% tergitol
(Nonidet P-10)), and the rate of inactivation of PON1 was
determined by monitoring arylesterase activity, as outlined
under “Experimental Procedures” (Fig. 13, A and B). This
approach has previously been used to examine and characterize
human and rabbit PON activity stabilities (76, 77). A very slow
inactivation of WT rPON1 was observed in the presence of
rHDL (Fig. 13A), consistent with previous reports that HDL
FIGURE5.Simplebasehydrolysis stepeffectively removes thebulkof the
lipid side delivering structurally informative and recognizable peptide
backbone fragmentations. Tandem mass spectrum of pac-PC modified
apoA-I peptide (Thr-161–Arg-171) after base hydrolysis. Amino acid and b/y
ions that carry hydrolyzed pac-PCmodification group (226.061) are labeled
with *.
FIGURE 6. Experimental scheme using pac-PC to investigate pac-PC-
rPON1 interactions. rHDL incorporating the 2 mol % pac-PC was incubated
with His-tagged rPON1, and cross-linkingwas performedwith brief exposure
to UV light (365 nm) and enriched by using Ni-NTA resin as described under
“Experimental Procedures.” Immobilized PON1-containing phospholipid
adducts were biotinylated via click chemistry and purified using neutravidin,
digested with trypsin, and processed as described in Fig. 2. Lipid adducted-
modified rPON1 peptides were eluted from the beads and base-treated to
remove bulk lipid and allow facile identification of the modification sites on
rPON1 by LC/MS/MS and searching for glycerol-phosphate-modified pep-
tides, which were detected by a static modification (226.061) applied to
each amino acid residue. Details are described under “Experimental
Procedures.”
TABLE 1
Identified rPON1 residues that cross-linkedwith the photoactivatable
lipid probe pac-PC
Three rPON1 peptides were reproducibly identified that carried the specific mod-
ification (226.061) corresponding to the glycerol phosphate adduct. The residue
within each peptide (Leu-9, Tyr-185, and Tyr-293) carrying the glycerol-phosphate
moiety derived from pac-PC is also shown, along with the excellent (within 10
ppm) agreement between the exact mass experimentally measured for each
peptide and its theoretical mass based on elemental composition. Mass spectra
were originally filtered by XCorr (cross-correlation value) and were examined
by manual inspection.
Labeled peptide
Labeled
residue [M  H] M X-Corr
ppm
2AKLTALTL*LGLGLALFDGQK21 Leu-9 2269.2962 4.70 4.57
291IFY*YDPK297 Tyr-293 1171.5417 4.18 2.29
180ATNDHY*FADPY190 Tyr-185 1539.6117 5.07 2.51
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particles stabilize PON1 activity (77). Addition of detergent
(0.1% tergitol, Nonidet P-10) to WT rPON1 showed an inter-
mediate rate of inactivation, whereas rPON1 incubated with
buffer alone showed a relatively rapid decay in activity (Fig.
13A). In contrast, no protective effects were observed when the
pan-K rPON1 mutant was incubated with either rHDL or
detergent (0.1% tergitol, Nonidet P-10), suggesting PON1
Leu-9, Tyr-185, and Tyr-293 additionally contribute to the
HDL-dependent stabilization of PON1 activity to thermal
denaturation and detergents.
Because PON1 Tyr-293 is photo-labeled by pac-PC to a
greater extent (estimated 10–20-fold) compared with the adja-
cent Tyr-294 residue, we decided to assess the functional sig-
nificance of each residue toHDLbinding/stabilization of PON1
activity. PON1Tyr-293 and Tyr-294 were individuallymutated
to Lys, and their PON1 activity (measured as arylesterase activ-
ity) was determined (Fig. 14A). PON1 Y293K and Y294K both
possess catalytic activity. Interestingly, the specific activity of
freshly isolated Y294Kmutant appears modestly reduced com-
paredwith theWTandY293K forms of the enzyme. To explore
the strength and functional impact of the HDL-PON1 interac-
tion with each PON1 residue, we further examined the stability
of each mutant (Y293K versus Y294K) to inactivation in the
presence or absence of rHDL, because both our studies (Fig. 13)
and those of others (76, 77) show this is an excellent functional
readout of the PON1-HDL interaction. Incubation of all PON1
forms (eitherWT or both mutants) in buffer containing EDTA
and -mercaptoethanol at 37 °C without HDL resulted in rapid
loss of activity (data not shown). However, in the presence of
HDL, the rate of PON1 inactivation in the WT versus mutant
PON1 forms was markedly different and followed the order
Y293K Y294KWT (Fig. 14B). WT PON1was completely
stabilized to inactivation by binding to HDL over the time
course examined. In contrast, Y293K was inactivated much
faster and was less stabilized by HDL than the Y294K mutant,
which showed intermediate deactivation rate (Fig. 14). These
results are consistent with the pac-PC labeling studies, which
suggest PON1 Tyr-293 plays a more significant role in PON1-
HDL binding than PON1 Tyr-294 (because the extent of
pac-PC labeling of Tyr-293 was 10–20-fold greater than
Tyr-294).
Discussion
This study is significant for two distinct reasons. First, in
general terms, it describes the development and characteriza-
tion of a novel photoactivatable, affinity-taggable (via click
chemistry), phospholipid probe (pac-PC) and the necessary
sample processing and mass spectrometry-based analytical
platform amenable for the facile discovery of specific residues
on proteins involved in docking to phospholipid surfaces.
Importantly, in addition to the inherent specificity and affinity
enrichment steps enabled by the probe design, the sample pro-
cessing and analyses methodology developed enables existing
mass spectrometry software programs to be used for automated
FIGURE 7. Illustration of tandem mass spectra from rPON1 peptide Ile-
291–Lys-297 and its cross-linking productwith pac-PC. The tandemmass
spectra shown are rPON1 peptide Ile-291–Lys-297 (A) and rPON1 peptide
Ile-291–Lys-297 (B), carrying a modification (226.061) at Tyr-293. The pac-
PC-modified amino acid and related b, y ions are labeled with *.
FIGURE 8. Crystal structure of rPON1 with highlighted residues that
cross-linked with photoactivatable lipid probes. Shown is an image of
human PON1 crystal structure (Protein Data Bank code 3SRE), with residues
participating in the HDL-binding interface highlighted. Leu-9 (which is not
shown on the structure), Tyr-185, and Tyr-293 (yellow) were identified that
cross-linked with pac-PC. Tyr-294 (cyan) was later identified that also cross-
linkedwith pac-PC butwithmuch lower abundance (less than 5%) compared
with Tyr-293, using the selective ionmonitoringmode. Tyr-71 (blue) was pre-
viously identified in cross-linking experiments. All of these residues are
located in the hypothetical HDL binding domain (above the dashed line,
according to PON1 crystal structure and hydropathy analyses).
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peptide identification, a significant advance over existing lipid
photoactivatable probes. Second, on amore specific level, use of
the novel probe, pac-PC, when incorporated into rHDL for
proof of concept studies, helped to define three key residues on
PON1 involved in HDL docking and stabilization of PON1 cat-
alytic activity (Leu-9, Tyr-185, and Tyr-293).
In prior studies, we sought to define precise residues on
PON1 that are involved in interaction with HDL cholesterol by
incorporating a synthetic photoactivatable cholesterol ana-
logue containing a diazirine moiety at C6 of the sterol into nas-
cent HDL (31). The diazirine group, because of its position and
hydrophilicity, is predicted to predominantly be exposed at the
surface of the HDL particle. Although one residue of PON1,
Tyr-71 (Fig. 8), was discovered in these early studies, the labo-
rious mass spectrometry analyses required to detect a choles-
tanyl adduct within a sea of PON1 peptides was a major limita-
tion of the approach. The absence of an affinity tag resulted in
extremely low abundance of photolabeled peptides (one in ten
thousand to million), making their identification tedious and
extremely difficult. The new tool developed herein has numer-
ous advantages. Importantly, it couples the specificity of a very
short lived diradical intermediate upon photoactivation with a
suitable affinity tag for enrichment (alkyne-azide-driven click
chemistry to biotinylate). During the preparation of this study,
a photoactivatable cholesterol probe with an affinity tag was
reported and applied to globally map cholesterol-protein
interactions in living cells (72). Instead, we designed a totally
different photoactivatable probe (an analogue of phosphatidyl-
choline) to investigate protein-membrane or lipoprotein in-
teractions. We originally chose to synthesize and characterize
FIGURE9.Significantdifferences in cross-linking formationbetweenpac-
PC/Tyr-293 versus pac-PC/Tyr-294 demonstrate the spatial sensitivity
and specificity of using pac-PC to interrogate lipid-protein interactions
at the interface of PON1 and HDL. A, chromatogram of the selective ion
monitoring m/z 586.3 corresponding to rPON1 peptide Ile-291–Lys-297 car-
rying hydrolyzed pac-PCmodification group (226.061). A new peptide that
has the same m/z value but slightly different retention time was isolated as
the small shoulder peak (peak 1) on the chromatogram. B, new isolated tan-
dem mass spectrum of rPON1 peptide Ile-291–Lys-297 carrying hydrolyzed
pac-PC modification group (226.061) at Tyr-294.
FIGURE 10. Characterizations of site-specific rPON1mutants. All mutants
were compared with the recombinant PON1 variant G3C9 (wild type like
activity, rPON1 WT). Residues (Leu-9, Tyr-185 and Tyr-293) were mutated to
either glutamic acid (rPON1 pan-E) or lysine (rPON1 pan-K). A, purified rPON1
WT, pan-E, and pan-K proteins were fractionated by 12% SDS-PAGE and
stained with Coomassie Blue. B, circular dichroism spectra of purified rPON1
WT, pan-E, and pan-K proteins. rPON1 forms (WT, pan-E, and pan-K mutants)
were analyzed at ambient temperature in continuous scanmodewith a 1-nm
bandwidth (100,000 counts/step). Details are described under “Experimental
Procedures.”
FIGURE 11. PON1 residues Leu-9, Tyr-185, and Tyr-293 are functionally
important for preservation of PON1 activity. A, paraoxonase activity; B,
arylesterase activity of purified rPON1WT, pan-E, andpan-Kmutants. Purified
rPON1 pan-K mutant demonstrated a specific activity of50% paraoxonase
activity and 80% arylesterase activity compared with rPON1 WT, whereas
rPON1 pan-E mutant demonstrated almost complete loss of activity with
either substrate. Data shown represent the mean 	 S.D. of triplicate
determinations.
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this probe design due to the simplicity of its chemical structure
and the relatively similar van derWaals size of the diazirine ring
versus the trimethylamine of the choline headgroupmoiety.We
also recognized that pac-PC is convenient to chemically syn-
thesize, and early control studies indicated it was stable enough
under ambient light exposure to simplify its use. Later, during
themass spectrometry analysis of cross-linked peptide adducts,
we found an unexpected advantage of this new probe that
greatly enhances its potential utility, i.e. its ability to be used
with commercial platformpeptide sequencing software. Specif-
ically, although the initial mass spectra obtained of lipid-ad-
ducted peptides were not easily recognized by current data
analysis programs, addition of a base-hydrolysis step to remove
the bulky lipid side chainswas found to simplify automated data
acquisition. Thus, using pac-PC under the methodology devel-
oped herein, mass spectra of glycerophosphate-tethered pep-
tides are readily recognized by extant state of the art data anal-
TABLE 2
The binding affinities between rPON1 mutants (WT, pan-E, and pan-K) and recombinant nascent HDL particles through surface plasmon
resonance
Recombinant nascent HDL was directly immobilized on a CM5 sensor chip. Samples of the indicated rPON1 ranging from 500 to 2000 nM were prepared in PON1 activity
buffers (50 mM Tris, 50 mM NaCl, 1 mM CaCl2, pH 8.0) and flowed over the surface of the sensor chip at a flow rate of 20 l/min. The association constant rate (kon),
dissociation constant rate (koff), and apparent dissociation constants (Kd) are listed in the table.
rPON1 Peptides with mutated amino acids kon (1/ms) koff (1/s) Kd (1/M)
WT 2AKLTALTLLGLGLALFDGQK21 1.2 103 8.5 107 7.1 1010
291IFYYDPK297
180ATNDHYFADPY190
pan-E 2AKLTALTELGLGLALFDGQK21 850 5.0 102 5.9 105
291IFEYDPK297
180ATNDHEFADPY190
pan-K 2AKLTALTKLGLGLALFDGQK21 42 6.0 105 1.4 106
291IFKYDPK297
180ATNDHKFADPY190
FIGURE 12. PON1 residues Leu-9, Tyr-185, and Tyr-293 are functionally
important forHDLbinding. Surface plasmon resonance sensorgrams of the
bindingof various concentrationsof rPON1are shown.A,WT;B,pan-Kmutant
to rHDL particles. rHDL was directly immobilized on a CM5 sensor chip. Sam-
ples of rPON1 ranging from 500 to 2000 nM were prepared in PON1 activity
buffers and flowed over the surface of the sensor chip as described under
“Experimental Procedures.” The apparent dissociation constants (Kd) were
obtained by fitting background-subtracted SPR binding data to the 1:1 bind-
ing with drifting baseline model within the BIAevaluation software version
4.0.
FIGURE 13. PON1 residues Leu-9, Tyr-185, and Tyr-293 are functionally
important to promote PON1 stabilization. Kinetics of the inactivation of
rPON1WT (A) pan-K (B) in the solution of excess rHDL particles, 0.1% tergitol,
or buffer only are shown. Recombinant PON1 WT and pan-K were preincu-
batedwith rHDLs (excess), 0.1% tergitol (NP-10), or PON1 activity buffer. Inac-
tivation was initiated by adding an equal volume of denaturing buffer and
incubating the samples as described under “Experimental Procedures.”
Aliquots were taken at the indicated time points, and arylesterase activi-
ties were examined. Data shown represent the mean 	 S.D. of triplicate
determinations.
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ysis programs (e.g. SEQUEST) by applying a static modification
of226.061 atomic mass units to each amino acid for peptide
analyses. This feature of the present methodology is unique,
and it markedly simplifies the identification process of affinity-
tagged peptides and the critical residue(s) involved in lipid
adduct formation.
Some potential limitations about pac-PC are worth noting.
The current probe design for pac-PC will likely preferentially
recognize a subset of residues on a docking protein, such as
those that are involved with the initial interaction at or near a
membrane surface or lipoprotein interface. Indeed, it is possi-
ble that the pac-PC design developed may not optimally inter-
rogate regions of lipid-binding proteins that penetrate far into
the acyl chain region of membrane bilayers or lipoproteins.
Based upon the methodology developed herein, however, one
can reasonably envision future development of alternative
pac-PC analogues where the diazirine group (or alternative
photoactivatable moiety) is placed at different positions along
one of the fatty acyl side chains to probe residues on docking
proteins that penetrate to greater depths of a hydrophobic
surface. Base hydrolysis of these would generate peptides
adducted to the fatty acyl moiety harboring the diazirine
group. Similarly, incorporation of the photo-affinity group
into phospholipids of alternative classes (headgroups), and
thus potential biological functionality, might further expand
the utility of these tools.
In our current application of probing the PON1-HDL inter-
face, visual inspection of the location of the PON1 residues
identified (Leu-9, Tyr-185 and Tyr-293) shows they are all
localized in close vicinity to a hypothetical PON1 hydrophobic
binding surface based upon a recently reported PON1 crystal
structure and hydropathy analyses (Fig. 8) (73). Of note, residue
Leu-9 is close to the N terminus of rPON1, which was not visu-
alized in the crystal structure. However, the N-terminal helix
(helix 1) of PON1 has previously been suggested to play an
important role in PON1-HDL interaction based upon deletion
mutant studies. Specifically, the recombinant PON1 truncated
variant (
20, lacking the first 20 amino acids) was reported to
have much lower binding affinity for HDL particles compared
with the full-length version (77). PON1 Tyr-185 is located on
the loop adjacent to helix 2, whereas Tyr-293 is at the end of
helix 3.However, they are all in relatively close spatial proximity
and together define an interfacial docking surface for PON1 on
HDL (Fig. 8). Prior studies have suggested helices 2 (Asp188-
Leu198) and 3 (Asn287-Tyr293) may potentially participate in
PON1-HDL interactions based on the analyses of the exposed
hydrophobic surfaces on the PON1 crystal structure (73), yet
no experimental validation nor specific residues in these
regions have been examined for their functional significance in
lipid binding. Interestingly, two hydrophobic residues (Tyr-190
and Trp-194) on helix 2, previously hypothesized to potentially
be involved in HDL anchoring based on their hydrophobicity
(73), were not identified to cross-link with the photo-lipid
probe in this study despite extensive searches for these adducts.
One possible explanation is that apoA-I of HDLmay prevent
contact between these PON1 residues and the photoactivat-
able lipid probe within the surface of the HDL particle. By
using hydrogen-deuterium exchange mass spectrometry
analysis, we previously identified two regions on apoA-I of
nascent HDL that interact with PON1 (31), and these pep-
tides are predicted to be in close spatial proximity (exactly
opposite to each other on the anti-parallel apoA-I chains of
nascent HDL) (78). Although speculative at present, it is
conceivable that these residues on PON1 helix 2 may directly
interact with the hydrophobic surface of one or both of these
two anti-parallel regions of apoA-I, thus reducing their
access to the phospholipid surface on HDL particles.
Another possibility is simply that neither of the two PON1
hydrophobic residues (Tyr-190 and Trp-194) on helix 2 play a
role in PON1-HDL interaction.
Our mutagenesis studies of PON1 Leu-9, Tyr-185, and Tyr-
293 confirm their functional significance for PON1-HDL inter-
action. The identified phospholipid adducts with residues Tyr-
185 andTyr-293 are consistent with a role of at least portions of
FIGURE 14. PON1 adjacent residues Tyr-293 and Tyr-294 play different
roles in PON1 activity and stabilization of PON1 through HDL interac-
tion. A, arylestrase activity of rPON1 WT, Y293K, and Y294K mutants in the
presence of rHDL are shown. B, kinetics of the inactivation of rPON1 WT,
Y293K, and Y294K mutants in the presence of excess HDL particles is shown.
rPON1WT, Y293K, and Y294K were preincubated with rHDLs as described
under “Experimental Procedures,” and inactivationwas initiatedbyaddingan
equal volume of denaturing buffer (containing metal chelator and reducing
agent) and incubating the samples at 37 °C as describedunder “Experimental
Procedures.” Aliquots were taken at the indicated time points, and aryles-
terase activity in reactions was determined. Data shown represent the
mean	 S.D. of triplicate determinations.
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helix 2 and 3 of PON1 functioning in the HDL interaction.
These studies thus provide structural information for how
these helix domains of PON1 are anchored to the HDL phos-
pholipid surface (via PON1 Tyr-185 and Tyr-293). Interest-
ingly, as shown in Fig. 8, the crystal structure of rPON1 (73)
reveals that the two adjacent tyrosine residues we examined in
detail (Tyr-293 and Tyr-294), although close, are positioned in
opposite orientations. Tyr-293, which was more readily identi-
fied as a covalent adduct to the photo-affinity phospholipid
probe (20-fold greater), faces toward the hypothetical HDL
lipid surface where it can support PON1 binding to the lipid
HDL phase. In contrast, the crystal structure predicts Tyr-294
is oriented virtually 180° in the opposite direction away from
the potential HDL-binding interface. Thus, despite the theoret-
ically equivalent reactivity of the phenol moiety of each residue
with a carbene diradical, and their close spatial proximity (the
-carbons of each Tyr are within 4.8 Å in the crystal structure
(73)), significant differences in the ease of covalent adduct for-
mationwas noted between these residues. Themarkedly differ-
ent orientation of the tyrosine residues likely explains this dif-
ference. This interesting finding also demonstrates the spatial
sensitivity and specificity of our approach to interrogate lipid-
protein interactions. It is also notable that our mutagenesis
studies verified that the Y293K mutant was less stable to dena-
turation in the presence of HDL compared with either Y294K
or WT PON1.
PON1 is an HDL-associated protein with cardioprotective
functions (36, 37). Its antioxidant and anti-inflammatory effects
have been extensively observed in vitro and in vivo (12, 31, 32,
36, 37, 79). Some pharmaceutical effort has even been aimed at
developing PON1, or PON1-HDL complexes, as an injectable
biological agent for various indications ranging from the treat-
ment of exposure to organophosphate nerve agents to the pre-
vention or treatment of cardiovascular diseases (80, 81). Pro-
gress in this arena has been hampered by poor stability of the
injected PON1 into the systemic circulation, and it has been
suggested that an improved understanding of specific struc-
tural features critical to PON1 docking to the HDL particle and
that are functionally important for maintenance of PON1 sta-
bility and catalytic activity may assist in these endeavors (82,
83). This study may thus help with future therapeutic agent
efforts using PON1.
Finally, our recent finding that PON1, myeloperoxidase,
and HDL form a functional ternary complex in vivo (31)
provides a unique perspective for the understanding of the
cardioprotective functions of PON1. Myeloperoxidase is a
leukocyte-derived heme protein that often initiates lipid per-
oxidation and protein oxidative damage during inflamma-
tion (43, 48, 84–87). The fact that PON1 binds to both
myeloperoxidase and HDL on the HDL surface, partially
inhibiting myeloperoxidase activity, was shown to also help
PON1 inhibit initiation of lipid peroxidation by myeloper-
oxidase. Alternative studies have suggested the lactonase
activity of PON1 contributes to its anti-oxidant activity
through hydrolysis of specific lipid peroxidation products
(88, 89). A better understanding of the critical residues sup-
porting PON1 interactions with HDL may thus help better
understand the mechanisms through which the protein
exerts its anti-oxidant and cardioprotective effects. Further
studies in this area seem warranted.
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